Want to see LGND full AI Analyst Report?
Ligand Pharma (LGND) Financial Statements
Ligand Pharma Financial Overview
Ligand Pharma's market cap is currently $6.43B. The company's EPS TTM is $2.59; its P/E ratio is 124.61; and it has a dividend yield of 5.35%. Ligand Pharma is scheduled to report earnings on March 4, 2027, and the estimated EPS forecast is $2.87. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 268.09M | $ 167.13M | $ 131.31M | $ 196.25M | $ 241.54M |
| Gross Profit | $ 261.50M | $ 156.06M | $ 96.27M | $ 143.42M | $ 179.37M |
| Operating Income | $ 47.20M | $ -22.61M | $ 11.94M | $ 3.04M | $ 103.85M |
| EBITDA | $ 192.74M | $ 40.79M | $ 100.84M | $ 81.20M | $ 142.77M |
| Net Income | $ 124.45M | $ -4.03M | $ 52.15M | $ -33.36M | $ 57.14M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 733.52M | $ 256.17M | $ 170.31M | $ 211.87M | $ 341.11M |
| Total Assets | $ 1.56B | $ 941.77M | $ 787.22M | $ 762.67M | $ 1.30B |
| Total Debt | $ 451.49M | $ 7.11M | $ 6.17M | $ 87.75M | $ 324.39M |
| Net Debt | $ 276.56M | $ -65.20M | $ -16.79M | $ 42.74M | $ 304.86M |
| Total Liabilities | $ 543.42M | $ 111.33M | $ 86.30M | $ 165.18M | $ 476.43M |
| Stockholders' Equity | $ 1.02B | $ 830.44M | $ 700.91M | $ 597.49M | $ 821.16M |
| Cash Flow | |||||
| Free Cash Flow | $ 48.91M | $ 77.41M | $ -4.27M | $ 119.93M | $ 70.04M |
| Operating Cash Flow | $ 49.36M | $ 97.05M | $ 49.58M | $ 137.85M | $ 78.80M |
| Investing Cash Flow | $ -377.32M | $ -143.66M | $ -11.68M | $ 163.62M | $ 30.52M |
| Financing Cash Flow | $ 428.22M | $ 97.14M | $ -59.95M | $ -275.99M | $ -137.76M |
Currency in USD